Namodenoson Positive Data in Ph 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient Announced March 31, 2026
FDA Accepts NDA Resubmission for Rivoceranib in Combination with Camrelizumab for 1L HCC March 31, 2026
NMPA Accepts New Drug Applications for Toripalimab Subcutaneous Injection Across 12 Indications March 10, 2026
Tempest plans to prioritize development of clinical-stage dual-targeting CD19/BCMA CAR-T program, TPST-2003 February 17, 2026
FAILED TRIAL: Ph 3 LEAP-012 trial of KEYTRUDA + LENVIMA + TACE combo in HCC patients did not achieve statistical significance for OS vs TACE alone November 4, 2025
HREC approves initiation of FIH Ph 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement October 15, 2025
Patients With Aggressive Brain and Advanced Liver Cancers Treated with PIC monotherapy Reach Five Years of Durable RFS September 23, 2025
First Patient Dosed in Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant HCC September 16, 2025
FDA & NMPA’s approval to initiate Ph 2 COMPASSION-36/AK104-225 registrational trial of cadonilimab + lenvatinib combo in IO-refractory HCC announced August 11, 2025
NMPA and FDA approve initiation of Ph 2 trial (COMPASSION-36/AK104-225) of cadonilimab combo in previously treated HCC patients August 5, 2025
Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Unresectable or Metastatic 1L HCC July 29, 2025
SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC July 15, 2025
NMPA clears application to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab in 1L metastatic HCC patients July 8, 2025
Tempest Receives Orphan Drug Designation from the EMA for Amezalpat for the Treatment of Patients with HCC June 10, 2025
Positive Results from Ph 3 TALENTACE Study of Tecentriq and Avastin for Unresectable HCC announced May 27, 2025
NMPA CDE grants Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC May 27, 2025
